TABLE 9.
Treatment effect for 5 year graft survival with imputation (i.e., all-cause and death-censored) is the log HR, while the 1 year full and abbreviated iBOX scores are the difference in medians.
| BELA | CSA | Treatment effect | p | ||
|---|---|---|---|---|---|
| Full iBOX | |||||
| BENEFIT RCT (n = 466) | iBox score at 12 months: Median (SD) | −3.502 (0.07) | −2.915 (0.10) | −0.587 | <.0001 |
| 5 years KM survival probability % (SD) | 96.0 (1.14) | 89.7 (2.67) | −0.999 | .02 | |
| BENEFIT-EXT RCT (n = 330) | iBox score at 12 months: Median (SD) | −2.6804 (0.065) | −2.1848 (0.12) | −0.4957 | .0005 |
| 5 years KM survival probability % (SD) | 94.50 (1.55) | 88.08 (3.43) | −0.8163 | .071 | |
| Abbreviated iBOX | |||||
| BENEFIT RCT (n = 599) | iBOX score at 12 months: Median (SD) | −3.679 (0.05) | −3.042 (0.08) | −0.637 | <.0001 |
| 5 years KM survival probability % (SD) | 96.3 (0.96) | 89.7 (2.44) | −1.058 | .006 | |
| BENEFIT-EXT RCT (n = 455) | iBOX score at 12 months: Median (SD) | −2.9057 (0.07) | −2.4255 (0.12) | −0.4803 | .0007 |
| 5 years KM survival probability % (SD) | 85.05 (2.15) | 78.54 (3.75) | −0.3292 | 0.2 | |
BELA, belatacept; CSA, cyclosporine; KM, Kaplan-Meier; RCT, randomized controlled trial; SD, standard deviation.